<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058677</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-21-0254</org_study_id>
    <nct_id>NCT05058677</nct_id>
  </id_info>
  <brief_title>Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury</brief_title>
  <official_title>Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of nebulized lidocaine before&#xD;
      Endotracheal suctioning (ETS) compared to instilled lidocaine and the effectiveness of&#xD;
      aerosolized lidocaine versus instilled normal saline before ETS in attenuating the increase&#xD;
      of intracranial pressure (ICP) in severe head injured children and to evaluate the&#xD;
      feasibility of a trial involving instilled lidocaine and aerosolized lidocaine for the&#xD;
      management of ETS and to evaluate the safety of nebulized lidocaine in traumatic brain injury&#xD;
      (TBI) compared to instilled lidocaine and instilled sodium chloride (NS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum difference between baseline ICP and highest ICP levels as measured by the ICP monitor in instilled lidocaine versus nebulized lidocaine</measure>
    <time_frame>from baseline to upto 15 minutes after ETS</time_frame>
    <description>A Codman Intraparenchymal Catheter will measure the ICP.The ICP will be transduced and measured numerically and continuously in real time on the patient's bedside monitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum difference between baseline ICP and highest ICP levels as measured by the ICP monitor in nebulized lidocaine and normal saline</measure>
    <time_frame>from baseline to up to 15 minutes after ETS</time_frame>
    <description>A Codman Intraparenchymal Catheter will measure the ICP.The ICP will be transduced and measured numerically and continuously in real time on the patient's bedside monitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with worsening respiratory dynamics</measure>
    <time_frame>from baseline to up to 15 minutes after ETS</time_frame>
    <description>This will be measured by increasing oxygenation index or worsening compliance, measured by any increase in the peak pressure for volume ventilated patients.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be performed before the endotracheal suctioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be performed before the endotracheal suctioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be performed before the endotracheal suctioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be performed before the endotracheal suctioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be performed before the endotracheal suctioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be performed before the endotracheal suctioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aerosolized 2% lidocaine (20mg/ml)</intervention_name>
    <description>The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.</description>
    <arm_group_label>Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution</arm_group_label>
    <arm_group_label>Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>instilled 0.9% sodium chloride (NS)</intervention_name>
    <description>The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.</description>
    <arm_group_label>Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution</arm_group_label>
    <arm_group_label>Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>instilled 2% lidocaine solution</intervention_name>
    <description>The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.</description>
    <arm_group_label>Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution</arm_group_label>
    <arm_group_label>Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endotracheal Suctioning (ETS)</intervention_name>
    <description>ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).</description>
    <arm_group_label>Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution</arm_group_label>
    <arm_group_label>Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine</arm_group_label>
    <arm_group_label>Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution</arm_group_label>
    <arm_group_label>aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to the PICU of Memorial Hermann Children's Hospital&#xD;
&#xD;
          -  Severe TBI with a Glasgow Coma Scale score 4-8&#xD;
&#xD;
          -  Intubated and mechanically ventilated with an ICP monitor in place.&#xD;
&#xD;
          -  Continuous invasive monitoring of arterial pressure&#xD;
&#xD;
          -  Hemodynamically Stable, defined by normal blood pressure for age before the ETS. We&#xD;
             will not exclude patients with norepinephrine to maintain goal blood pressures to&#xD;
             maintain Cerebral perfusion pressure(CPP).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with sustained ICP &gt; 25 for more than 30 minutes mm Hg despite medical or&#xD;
             neurosurgical intervention&#xD;
&#xD;
          -  Moderate/Severe Acute respiratory distress syndrome (ARDS) with an oxygenation index &gt;&#xD;
             8&#xD;
&#xD;
          -  Pulmonary hemorrhage&#xD;
&#xD;
          -  Patients receiving neuromuscular blockade&#xD;
&#xD;
          -  Use of other vasopressors for other causes of shock (cardiogenic, hypovolemic and&#xD;
             septic)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheikh Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheikh S Ahmed, MD</last_name>
    <phone>(713) 500-5553</phone>
    <email>Sheikh.S.Ahmed@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Viswamitra Ragoonanan, MD</last_name>
    <phone>(713) 500-5650</phone>
    <email>Viswamitra.Ragoonanan@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sheikh S Ahmed, MD</last_name>
      <phone>713-500-5553</phone>
      <email>Sheikh.S.Ahmed@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Viswamitra Ragoonanan, MD</last_name>
      <phone>(713) 500-5650</phone>
      <email>Viswamitra.Ragoonanan@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Sheikh Sohail Ahmed</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>lidocaine</keyword>
  <keyword>brain injury</keyword>
  <keyword>intracranial pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

